Concurrent Investment Advisors LLC Makes New $325,000 Investment in Koninklijke Philips N.V. (NYSE:PHG)

Concurrent Investment Advisors LLC acquired a new stake in shares of Koninklijke Philips N.V. (NYSE:PHG - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,795 shares of the technology company's stock, valued at approximately $325,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PHG. Sei Investments Co. lifted its position in shares of Koninklijke Philips by 5.2% during the 4th quarter. Sei Investments Co. now owns 308,673 shares of the technology company's stock worth $7,816,000 after buying an additional 15,395 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Koninklijke Philips by 107.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 129,624 shares of the technology company's stock valued at $3,282,000 after acquiring an additional 67,289 shares during the last quarter. QRG Capital Management Inc. grew its stake in Koninklijke Philips by 11.0% in the 1st quarter. QRG Capital Management Inc. now owns 142,595 shares of the technology company's stock valued at $3,622,000 after acquiring an additional 14,090 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Koninklijke Philips in the 4th quarter valued at about $10,655,000. Finally, Aurora Private Wealth Inc. acquired a new stake in shares of Koninklijke Philips during the 1st quarter worth about $1,695,000. 13.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on PHG shares. Sanford C. Bernstein upgraded shares of Koninklijke Philips from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 18th. Wall Street Zen raised shares of Koninklijke Philips from a "hold" rating to a "buy" rating in a research report on Saturday. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy".

Koninklijke Philips Stock Performance

Shares of Koninklijke Philips stock traded up $0.06 during trading on Tuesday, hitting $24.10. 604,476 shares of the stock were exchanged, compared to its average volume of 908,040. The stock's fifty day moving average is $23.56 and its 200 day moving average is $24.95. The stock has a market cap of $23.20 billion, a PE ratio of 56.04, a P/E/G ratio of 0.68 and a beta of 0.76. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.79 and a current ratio of 1.28. Koninklijke Philips N.V. has a 12 month low of $20.61 and a 12 month high of $31.57.

Koninklijke Philips (NYSE:PHG - Get Free Report) last released its earnings results on Tuesday, May 6th. The technology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.14 by $0.13. The firm had revenue of $4.31 billion for the quarter, compared to analysts' expectations of $4.10 billion. Koninklijke Philips had a net margin of 2.11% and a return on equity of 10.97%. Koninklijke Philips's quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the company earned $0.21 EPS. As a group, sell-side analysts anticipate that Koninklijke Philips N.V. will post 1.63 EPS for the current year.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.